A “Forbeck Forum” is an intimate venue for open discussion, sharing, and collaboration. The Forum is limited to 15-20 participants who represent the best of the best in oncology expertise from around the world.  Past participants propose topics for Forums.  The topic, chairs, and participants are approved by the WGFRF Scientific Advisory Board. 

To encourage open discussion and debate the participants are only allowed to present 5 slides.  Often, there is too much discussion to get through all 5 slides.  This protected environment allows for real advancement in cancer research and collaborations.  The model implemented for the Forum is now duplicated by many other organizations.  Although it can be hard to quantify the results of these meetings,  Forbeck Forums are highly regarded in the cancer research community and it is an honor to participate.

Key Objectives

  • Establish new and novel approaches in research to improve detection, treatment and cure rates in cancer.

  • Bridge the gap between institutions and scientific specializations to advance treatment.

  • Expediting cancer research by forming new and lasting collaborations and relationships with fellow scientists.

Past participants and Forbeck Scholars are welcome to submit a Forum topic to the Foundation. The Scientific Advisory Board will review the topic proposals on a quarterly basis.


Below is a listing of all forums held over our 30 years and links to summaries where applicable.

2019 – Cancer And Aging
Marcia Haigis, PhD, Harvard Medical School, Boston, MA
Steve Artandi MD, PhD, Stanford University, Stanford, CA

2019 – Telomerase-Mediated Telomere Targeting in Cancer
Titia de Lange, Ph.D., Rockefeller University
Jerry W. Shay, Ph.D., UT Southwestern

2019 – Leukemia stem cells, heterogeneity, and metabolism - new directions for AML therapy
Martin Carroll, MD, University of Pennsylvania
Craig T. Jordan, Ph.D., University of Colorado
Aaron Schimmer, MD, Ph.D., Princess Margaret Cancer Center

2019 – DIPG Consensus Meeting
Oren Becher, MD, Northwestern University
Cynthia Hawkins, MD, Ph.D., The Hospital for Sick Kids

2019 – 3D Chromosomal Architecture and Nuclear Topology
Ari Melnick, MD, Weill Cornell Medical College, New York, NY
Jane Skok, Ph.D., New York University, New York, NY 

2018 – Cancer Predisposition
John M. Maris, MD, Children’s Hospital of Philadelphia, Philadelphia
Judy E. Garber, MD, MPH, Dana Farber Cancer Institute, Boston, MA

2018 – Tumor Microenvironment
Lisa Coussens, Ph.D., Oregon Health and Sciences University, Portland, OR
Rakesh Jain, Ph.D., Harvard Medical School, Boston, MA

2018 – Epigenetic Therapy
Jean-Pierre Issa, MD, Temple University, Philadelphia, PA
Peter Jones, Ph.D., Van Andel Institute, Grand Rapids, MI
Stephen Baylin, MD, Johns Hopkins Medical School, Baltimore, MD

2018 – Metabolic Signaling and the Epigenome: Illuminating Basic mechanisms and paths to translation
Julie-Aurore Losman, MD, Ph.D., Dana Farber Cancer Institute, Boston, MA
Kathryn Wellen, Ph.D., University of Pennsylvania, Philadelphia, PA 

2017 – Precision Cancer Medicine in Functional Biomarkers
Anthony Letai, MD, Ph.D., Dana Farber Cancer Institute, Boston, MA 

2017 – Convergence of MYC and RAS in Cancer
Karen Cichowski, Ph.D., Brigham and Women’s Hospital, Boston, MA
Gerard Evan, Ph.D., University of Cambridge, Cambridge, England

2016 – Renal Medullary Carcinoma
W. Kimryn Rathmell, MD, Ph.D., Vanderbilt University, Nashville, TN
Nizar Tannir, MD, MD Anderson Cancer Center, Houston, TX

2016 – Chromosomal Instability/Aneuploidy
Angelika Amon, Ph.D., Koch Institute at MIT, Cambridge, MA
David Pellman, MD, Dana Farber Cancer Institute, Boston, MA

2015 – Cancer Immunotherapy
Catherine Bollard, MD, National Children’s Health, Washington D.C.
Daniel Powell, Ph.D., University of Pennsylvania, Philadelphia, PA

2014 – Invasion And Metastasis
Ann F. Chambers, Ph.D., London Health Sciences Center, Toronto, Canada
Zena Werb, Ph.D., University of California San Francisco, CA

2014 – Extracellular Vesicles: Promises and Pitfalls
Clark Chen, MD, Ph.D., University of California, San Diego, CA

2013 – Resistance Mechanisms
Joan Brugge, Ph.D., Harvard Medical School, Boston, MA
Jeffrey A. Engelman, Ph.D., Massachusetts General Hospital, Boston, MA

2012 – Tumor Metabolism
Lewis C. Cantley, Ph.D., Weill Cornell Medical College, New York, NY
Eileen White, Ph.D., The Cancer Institute Of New Jersey, New Brunswick, NJ

2012 – By Passing The Blood Brain Barriers To Improve Drug Delivery To Tumors In The Central Nervous System
Oren Becher, MD, Duke University, Durham, NC
Robert Wechsler-Reya, Ph.D., Sanford-Burnham Institute, La Jolla, CA

2011 – Epigenetics & Drug Therapy
Scott Armstrong, MD, Ph.D., Dana Farber Cancer Institute,  Boston, MA
Steven Henikoff, Phd, Fred Hutchinson Cancer Research Center, Seattle, WA

2011 – Childhood Germ Cell Tumors: Origins, Models & New Treatment Paradigms
James Amatruda, MD, Ph.D., UT Southwestern, Dallas, TX
Lindsay Frazier, MD, Dana Farber Cancer Institute, Boston, MA

2010 – Cancer Genomics
Richard Kolodner, Ph.D., University Of California, San Diego, CA
Michael R. Stratton, Frcpath, Sanger Institute, Cambridge, England

2009 – The Biology And Treatment Of Primary Brain Tumors
Tracy Batchelor, M.D., M.P.H., Harvard Medical School, Boston, MA
Andluis F. Parada, Ph.D., UT Southwestern, Dallas, TX 

2008 – Immunotherapy And Breaking Tolerance
James P. Allison, Ph.D., Memorial Sloan Kettering, New York, NY
Stanley Riddell, MD, Fred Hutchinson Cancer Research Center, Seattle, WA

2007 – Micro RNA And Cancer
Carlo M. Croce, MD, Ohio State University, Columbus, OH
Gregory J. Hannon, Ph.D., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

2006 – Stem Cells
John E. Dick, Ph.D., University Of Toronto, Toronto, Canada
David Scadden, MD, Massachusetts General Hospital, Boston, MA 

2005 – Innovations In Imaging In Cancer Research
Harvey R. Herschman, Ph.D., University Of California, Los Angeles, CA
Ralph Weissleder, MD, Ph.D., Massachusetts General Hospital, Boston, MA

2004 – Molecular Targets In Pediatric Malignancies
D. Gary Gilliland, Ph.D., MD, Howard Hughes Medical Institute, Chevy Chase, MDCharles L. Sawyers, MD, University Of California, Los Angeles, CA

2004 – Fertility And Reproductive Issues In Survivors Of Childhood Cancer
Charles Sklar, MD, Memorial Sloan Kettering, New York, NY
        
2003 – DNA Damage & Cancer Susceptibility Syndromes
Alan D'andrea, MD, Dana Farber Cancer Research Institute, Boston, MA
Jan Hoeijmakers, Erasmus University 

2003 – The New Biology Of Enigmatic Neuroblastoma and Relevant Treatment Strategies
Moritz M. Ziegler, MD, The Children’s Hospital, Boston, MA

2002 – Cellular Senescence & Cancer
Ronald Depinho, MD, Harvard Medical School, Boston, MA
Charles Sherr, Md, Phd, St. Jude Children’s Research Hospital, Memphis, TN

2002 – A New Tool In Cancer Medicine: Exploiting The Patient’s Immunological Memory
Volker Schirrmacher, German Cancer Research Center, Heidelberg, Germany
Philipp Beckhove, German Cancer Research Center, Munich, Germany

2001 – Differentiation As Cancer Therapy
Raymond Paul Warrell, Jr. MD, Genta Incorporated, Berkeley Heights, NJ

2001 – Mechanisms, Consequences, And Therapeutic Implications Of Blood Vessel Leakiness In Cancer
Donald M. Mcdonald, Ph.D., University Of California, San Francisco, CA

2000 – Allogeneic Stem Cell Transplantation
Frederick R. Appelbaum, MD, Fred Hutchinson Cancer Research Center, Seattle, WA

2000 – Proteases As Cancer Therapeutic Targets
Lynn M. Matrisian, Ph.D., Vanderbilt University, Nashville, TX

1999 – Dendritic Cell Approaches To Immunotherapy
Bruce A. Chabner, MD, National Cancer Institute, Bethesda, MD

1999 – Infant Leukemia
John Kersey, MD, Norma K. Ramsay, MD And Leslie Robinson, Ph.D.

1999 – Tumor Invasion And Metastasis
Arnold I. Freeman, MD, Hadassah University
Israel Vlodavsky, Tumor Biology Research Institute 

1999 – Targeting Gene Therapy – A Reality?
John D. Minna, MD, UT Southwestern, Dallas, TX
Inder Verma, Ph.D., Salk Institute, La Jolla, CA 

1998 – Angiogenesis And Accessibility
Judah Folkman, MD, Harvard Medical School, Boston, MA
Rakesh K. Jain, Ph.D., Harvard Medical School, Boston, MA

1997 – Second Malignancies
Carlo M. Croce, MD, Jefferson Cancer Center, Philadelphia, PA 

1996 – Specific Simple Models To Clinical Disease
Richard Klausner, MD, National Cancer Institute, Bethesda, MD

1995 – Apoptosis
John T. Isaacs, Ph.D., Johns Hopkins University, Baltimore, MD

1994 – Cell Cycle Checkpoints
Leland Hartwell, Ph.D., University Of Washington, Seattle, WA

1993 – Growth Factors
John Mendelsohn, MD, Memorial Sloan Kettering, New York, NY

1992 – Gene Therapy & Tumor Vaccines
Drew Pardoll, MD, Ph.D, Johns Hopkins University, Baltimore, MD

1991 – Dose Intensification In Pediatric Malignancies
Bruce A. Chabner, MD, National Cancer Institute, Bethesda, MD 

1990 – Molecular Origins Of Pediatric Embryonal Malignancies
Mark A. Israel, MD, University Of California, San Francisco, CA

1989 – Infectious Complications
 Philip A Pizzo, MD, National Cancer Institute, Bethesda, MD 

1988 – Improved Drug Delivery To Brain Tumors
Arnold I. Freeman, MD, University Of Missouri, Kansas City, MO

1987 – Reasons For Drug Failure
Bruce Chabner, MD, National Cancer Institute, Bethesda, MD

1986 – Tumor Progression & Differentiation
Isaiah J. Fidler, Dvm, Ph.D., Md Anderson Hospital, Houston, TX

1985 – Neuroblastoma
Arnold Freeman, Md, Roswell Park Memorial Institute, Buffalo, NY